{
  "description": "Diese ConceptMap dokumentiert ausschließlich die ATC-Code-Änderungen von 2020 zu 2021. Im Jahr 2021 erfolgte eine umfassende Reorganisation der ATC-Klassifikation für onkologische Substanzen mit Umkodierung von über 60 Wirkstoffen.",
  "sourceCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2020",
  "_filename": "ConceptMap-mii-cm-onko-atc-transitions-2021.json",
  "package_name": "de.medizininformatikinitiative.kerndatensatz.onkologie",
  "date": "2024-12-12",
  "group": [ {
    "source": "http://fhir.de/CodeSystem/bfarm/atc",
    "target": "http://fhir.de/CodeSystem/bfarm/atc",
    "element": [ {
      "code": "L01XE01",
      "target": [ {
        "code": "L01EA01",
        "comment": "Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren",
        "display": "Imatinib",
        "equivalence": "equivalent"
      } ],
      "display": "Imatinib"
    }, {
      "code": "L01XE06",
      "target": [ {
        "code": "L01EA02",
        "display": "Dasatinib",
        "equivalence": "equivalent"
      } ],
      "display": "Dasatinib"
    }, {
      "code": "L01XE08",
      "target": [ {
        "code": "L01EA03",
        "display": "Nilotinib",
        "equivalence": "equivalent"
      } ],
      "display": "Nilotinib"
    }, {
      "code": "L01XE14",
      "target": [ {
        "code": "L01EA04",
        "display": "Bosutinib",
        "equivalence": "equivalent"
      } ],
      "display": "Bosutinib"
    }, {
      "code": "L01XE24",
      "target": [ {
        "code": "L01EA05",
        "display": "Ponatinib",
        "equivalence": "equivalent"
      } ],
      "display": "Ponatinib"
    }, {
      "code": "L01XE02",
      "target": [ {
        "code": "L01EB01",
        "comment": "Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren",
        "display": "Gefitinib",
        "equivalence": "equivalent"
      } ],
      "display": "Gefitinib"
    }, {
      "code": "L01XE03",
      "target": [ {
        "code": "L01EB02",
        "display": "Erlotinib",
        "equivalence": "equivalent"
      } ],
      "display": "Erlotinib"
    }, {
      "code": "L01XE13",
      "target": [ {
        "code": "L01EB03",
        "display": "Afatinib",
        "equivalence": "equivalent"
      } ],
      "display": "Afatinib"
    }, {
      "code": "L01XE35",
      "target": [ {
        "code": "L01EB04",
        "display": "Osimertinib",
        "equivalence": "equivalent"
      } ],
      "display": "Osimertinib"
    }, {
      "code": "L01XE15",
      "target": [ {
        "code": "L01EC01",
        "comment": "Reklassifizierung zu BRAF-Inhibitoren",
        "display": "Vemurafenib",
        "equivalence": "equivalent"
      } ],
      "display": "Vemurafenib"
    }, {
      "code": "L01XE23",
      "target": [ {
        "code": "L01EC02",
        "display": "Dabrafenib",
        "equivalence": "equivalent"
      } ],
      "display": "Dabrafenib"
    }, {
      "code": "L01XE46",
      "target": [ {
        "code": "L01EC03",
        "display": "Encorafenib",
        "equivalence": "equivalent"
      } ],
      "display": "Encorafenib"
    }, {
      "code": "L01XE16",
      "target": [ {
        "code": "L01ED01",
        "comment": "Reklassifizierung zu ALK-Inhibitoren",
        "display": "Crizotinib",
        "equivalence": "equivalent"
      } ],
      "display": "Crizotinib"
    }, {
      "code": "L01XE28",
      "target": [ {
        "code": "L01ED02",
        "display": "Ceritinib",
        "equivalence": "equivalent"
      } ],
      "display": "Ceritinib"
    }, {
      "code": "L01XE36",
      "target": [ {
        "code": "L01ED03",
        "display": "Alectinib",
        "equivalence": "equivalent"
      } ],
      "display": "Alectinib"
    }, {
      "code": "L01XE43",
      "target": [ {
        "code": "L01ED04",
        "display": "Brigatinib",
        "equivalence": "equivalent"
      } ],
      "display": "Brigatinib"
    }, {
      "code": "L01XE44",
      "target": [ {
        "code": "L01ED05",
        "display": "Lorlatinib",
        "equivalence": "equivalent"
      } ],
      "display": "Lorlatinib"
    }, {
      "code": "L01XE25",
      "target": [ {
        "code": "L01EE01",
        "comment": "Reklassifizierung zu MEK-Inhibitoren",
        "display": "Trametinib",
        "equivalence": "equivalent"
      } ],
      "display": "Trametinib"
    }, {
      "code": "L01XE38",
      "target": [ {
        "code": "L01EE02",
        "display": "Cobimetinib",
        "equivalence": "equivalent"
      } ],
      "display": "Cobimetinib"
    }, {
      "code": "L01XE41",
      "target": [ {
        "code": "L01EE03",
        "display": "Binimetinib",
        "equivalence": "equivalent"
      } ],
      "display": "Binimetinib"
    }, {
      "code": "L01XE33",
      "target": [ {
        "code": "L01EF01",
        "comment": "Reklassifizierung zu CDK4/6-Inhibitoren",
        "display": "Palbociclib",
        "equivalence": "equivalent"
      } ],
      "display": "Palbociclib"
    }, {
      "code": "L01XE42",
      "target": [ {
        "code": "L01EF02",
        "display": "Ribociclib",
        "equivalence": "equivalent"
      } ],
      "display": "Ribociclib"
    }, {
      "code": "L01XE50",
      "target": [ {
        "code": "L01EF03",
        "display": "Abemaciclib",
        "equivalence": "equivalent"
      } ],
      "display": "Abemaciclib"
    }, {
      "code": "L01XE09",
      "target": [ {
        "code": "L01EG01",
        "comment": "Reklassifizierung zu mTOR-Inhibitoren",
        "display": "Temsirolimus",
        "equivalence": "equivalent"
      } ],
      "display": "Temsirolimus"
    }, {
      "code": "L01XE10",
      "target": [ {
        "code": "L01EG02",
        "display": "Everolimus",
        "equivalence": "equivalent"
      } ],
      "display": "Everolimus"
    }, {
      "code": "L01XE07",
      "target": [ {
        "code": "L01EH01",
        "comment": "Reklassifizierung zu HER2-Inhibitoren",
        "display": "Lapatinib",
        "equivalence": "equivalent"
      } ],
      "display": "Lapatinib"
    }, {
      "code": "L01XE45",
      "target": [ {
        "code": "L01EH02",
        "display": "Neratinib",
        "equivalence": "equivalent"
      } ],
      "display": "Neratinib"
    }, {
      "code": "L01XE18",
      "target": [ {
        "code": "L01EJ01",
        "comment": "Reklassifizierung zu JAK-Inhibitoren",
        "display": "Ruxolitinib",
        "equivalence": "equivalent"
      } ],
      "display": "Ruxolitinib"
    }, {
      "code": "L01XE17",
      "target": [ {
        "code": "L01EK01",
        "comment": "Reklassifizierung zu VEGFR-Inhibitoren",
        "display": "Axitinib",
        "equivalence": "equivalent"
      } ],
      "display": "Axitinib"
    }, {
      "code": "L01XE34",
      "target": [ {
        "code": "L01EK03",
        "display": "Tivozanib",
        "equivalence": "equivalent"
      } ],
      "display": "Tivozanib"
    }, {
      "code": "L01XE27",
      "target": [ {
        "code": "L01EL01",
        "comment": "Reklassifizierung zu BTK-Inhibitoren",
        "display": "Ibrutinib",
        "equivalence": "equivalent"
      } ],
      "display": "Ibrutinib"
    }, {
      "code": "L01XE51",
      "target": [ {
        "code": "L01EL02",
        "display": "Acalabrutinib",
        "equivalence": "equivalent"
      } ],
      "display": "Acalabrutinib"
    }, {
      "code": "L01XX47",
      "target": [ {
        "code": "L01EM01",
        "comment": "Reklassifizierung zu PI3K-Inhibitoren",
        "display": "Idelalisib",
        "equivalence": "equivalent"
      } ],
      "display": "Idelalisib"
    }, {
      "code": "L01XX61",
      "target": [ {
        "code": "L01EM02",
        "display": "Copanlisib",
        "equivalence": "equivalent"
      } ],
      "display": "Copanlisib"
    }, {
      "code": "L01XE04",
      "target": [ {
        "code": "L01EX01",
        "comment": "Reklassifizierung zu andere Proteinkinase-Inhibitoren",
        "display": "Sunitinib",
        "equivalence": "equivalent"
      } ],
      "display": "Sunitinib"
    }, {
      "code": "L01XE05",
      "target": [ {
        "code": "L01EX02",
        "display": "Sorafenib",
        "equivalence": "equivalent"
      } ],
      "display": "Sorafenib"
    }, {
      "code": "L01XE12",
      "target": [ {
        "code": "L01EX04",
        "display": "Vandetanib",
        "equivalence": "equivalent"
      } ],
      "display": "Vandetanib"
    }, {
      "code": "L01XE21",
      "target": [ {
        "code": "L01EX05",
        "display": "Regorafenib",
        "equivalence": "equivalent"
      } ],
      "display": "Regorafenib"
    }, {
      "code": "L01XE26",
      "target": [ {
        "code": "L01EX07",
        "display": "Cabozantinib",
        "equivalence": "equivalent"
      } ],
      "display": "Cabozantinib"
    }, {
      "code": "L01XE29",
      "target": [ {
        "code": "L01EX08",
        "display": "Lenvatinib",
        "equivalence": "equivalent"
      } ],
      "display": "Lenvatinib"
    }, {
      "code": "L01XE31",
      "target": [ {
        "code": "L01EX09",
        "display": "Nintedanib",
        "equivalence": "equivalent"
      } ],
      "display": "Nintedanib"
    }, {
      "code": "L01XE39",
      "target": [ {
        "code": "L01EX10",
        "display": "Midostaurin",
        "equivalence": "equivalent"
      } ],
      "display": "Midostaurin"
    }, {
      "code": "L01XE52",
      "target": [ {
        "code": "L01EX11",
        "display": "Quizartinib",
        "equivalence": "equivalent"
      } ],
      "display": "Quizartinib"
    }, {
      "code": "L01XE53",
      "target": [ {
        "code": "L01EX12",
        "display": "Larotrectinib",
        "equivalence": "equivalent"
      } ],
      "display": "Larotrectinib"
    }, {
      "code": "L01XE54",
      "target": [ {
        "code": "L01EX13",
        "display": "Gilteritinib",
        "equivalence": "equivalent"
      } ],
      "display": "Gilteritinib"
    }, {
      "code": "L01XX14",
      "target": [ {
        "code": "L01XF01",
        "comment": "Reklassifizierung zu Retinoide",
        "display": "Tretinoin",
        "equivalence": "equivalent"
      } ],
      "display": "Tretinoin"
    }, {
      "code": "L01XX22",
      "target": [ {
        "code": "L01XF02",
        "display": "Alitretinoin",
        "equivalence": "equivalent"
      } ],
      "display": "Alitretinoin"
    }, {
      "code": "L01XX25",
      "target": [ {
        "code": "L01XF03",
        "display": "Bexaroten",
        "equivalence": "equivalent"
      } ],
      "display": "Bexaroten"
    }, {
      "code": "L01XX32",
      "target": [ {
        "code": "L01XG01",
        "comment": "Reklassifizierung zu Proteasom-Inhibitoren",
        "display": "Bortezomib",
        "equivalence": "equivalent"
      } ],
      "display": "Bortezomib"
    }, {
      "code": "L01XX45",
      "target": [ {
        "code": "L01XG02",
        "display": "Carfilzomib",
        "equivalence": "equivalent"
      } ],
      "display": "Carfilzomib"
    }, {
      "code": "L01XX50",
      "target": [ {
        "code": "L01XG03",
        "display": "Ixazomib",
        "equivalence": "equivalent"
      } ],
      "display": "Ixazomib"
    }, {
      "code": "L01XX38",
      "target": [ {
        "code": "L01XH01",
        "comment": "Reklassifizierung zu Histon-Deacetylase-Inhibitoren",
        "display": "Vorinostat",
        "equivalence": "equivalent"
      } ],
      "display": "Vorinostat"
    }, {
      "code": "L01XX39",
      "target": [ {
        "code": "L01XH02",
        "display": "Romidepsin",
        "equivalence": "equivalent"
      } ],
      "display": "Romidepsin"
    }, {
      "code": "L01XX42",
      "target": [ {
        "code": "L01XH03",
        "display": "Panobinostat",
        "equivalence": "equivalent"
      } ],
      "display": "Panobinostat"
    }, {
      "code": "L01XX49",
      "target": [ {
        "code": "L01XH04",
        "display": "Belinostat",
        "equivalence": "equivalent"
      } ],
      "display": "Belinostat"
    }, {
      "code": "L01XX43",
      "target": [ {
        "code": "L01XJ01",
        "comment": "Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren",
        "display": "Vismodegib",
        "equivalence": "equivalent"
      } ],
      "display": "Vismodegib"
    }, {
      "code": "L01XX63",
      "target": [ {
        "code": "L01XJ03",
        "display": "Glasdegib",
        "equivalence": "equivalent"
      } ],
      "display": "Glasdegib"
    }, {
      "code": "L01XX46",
      "target": [ {
        "code": "L01XK01",
        "comment": "Reklassifizierung zu PARP-Inhibitoren",
        "display": "Olaparib",
        "equivalence": "equivalent"
      } ],
      "display": "Olaparib"
    }, {
      "code": "L01XX54",
      "target": [ {
        "code": "L01XK02",
        "display": "Niraparib",
        "equivalence": "equivalent"
      } ],
      "display": "Niraparib"
    }, {
      "code": "L01XX60",
      "target": [ {
        "code": "L01XK04",
        "display": "Talazoparib",
        "equivalence": "equivalent"
      } ],
      "display": "Talazoparib"
    }, {
      "code": "L01XX17",
      "target": [ {
        "code": "L01CE01",
        "comment": "Reklassifizierung zu Topoisomerase-I-Inhibitoren",
        "display": "Topotecan",
        "equivalence": "equivalent"
      } ],
      "display": "Topotecan"
    }, {
      "code": "L01XX19",
      "target": [ {
        "code": "L01CE02",
        "display": "Irinotecan",
        "equivalence": "equivalent"
      } ],
      "display": "Irinotecan"
    } ]
  } ],
  "publisher": "Medizininformatik Initiative",
  "purpose": "Migration von ATC-Codes für Substanzen, die 2021 umkodiert wurden. Enthält nur geänderte Codes, keine neuen oder unveränderten Einträge.",
  "name": "MII_CM_Onko_ATC_Transitions_2021",
  "type": null,
  "experimental": "false",
  "resourceType": "ConceptMap",
  "title": "MII CM Onko ATC Code Changes 2020 to 2021",
  "package_version": "2026.0.0-rc.5",
  "targetCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2021",
  "status": "active",
  "id": "9c260d1a-353a-418f-aa19-52267f9e7251",
  "kind": null,
  "url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2021",
  "version": "2026.0.0-ballot",
  "contact": [ {
    "name": "Medizininformatik Initiative",
    "telecom": [ {
      "value": "https://www.medizininformatik-initiative.de/",
      "system": "url"
    } ]
  } ]
}